Sodium Carbonate → 6-(1H-indazol-5-yl)-N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine

HRID 1755350Notes

Reaction equation

HRID 1755350 reaction equation
Cl[C:2]1[CH:3]=[C:4]([NH:11][C:12]2[CH:17]=[CH:16][CH:15]=[C:14]([N:18]3[CH2:22][CH2:21][CH2:20][CH:19]3[CH3:23])[N:13]=2)[C:5]2[N:6]([CH:8]=[CH:9][N:10]=2)[N:7]=1.CC1(C)C(C)(C)OB([C:32]2[CH:33]=[C:34]3[C:38](=[CH:39][CH:40]=2)[NH:37][N:36]=[CH:35]3)O1.CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C.C([O-])([O-])=O.[Na+].[Na+]>O1CCOCC1.O.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[NH:37]1[C:38]2[C:34](=[CH:33][C:32]([C:2]3[CH:3]=[C:4]([NH:11][C:12]4[CH:17]=[CH:16][CH:15]=[C:14]([N:18]5[CH2:22][CH2:21][CH2:20][CH:19]5[CH3:23])[N:13]=4)[C:5]4[N:6]([CH:8]=[CH:9][N:10]=4)[N:7]=3)=[CH:40][CH:39]=2)[CH:35]=[N:36]1

Participants

8

Reactant 4

HCID 10340Sodium CarbonateHCID 111557942-Dicyclohexylphosphino-2',4',6'-triisoprophylbiphenylHCID 177504691H-Indazole-5-boronic acid pinacol esterHCID 715343846-chloro-N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine

Product 1

HCID 715258996-(1H-indazol-5-yl)-N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amineYield 38.5%

Reagents, catalysts & solvents 3

HCID 9811564Bis(dibenzylideneacetone)palladiumCatalystHCID 962WaterSolventHCID 312751,4-DioxaneSolvent

Conditions

Temperature
100 °C

Procedure

A mixture of 6-chloro-N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine (0.1 g, 0.304 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (0.082 g, 0.33 mmol), Pd2(dba)3 (0.035 g, 0.061 mmol), X-phos (0.058 g, 0.122 mmol) and Na2CO3 (0.097 g, 0.912 mmol) in dioxane (20 mL) and water (10 mL) was heated to 100° C. for 16 h in a sealed tube under N2 atmosphere then concentrated in vacuo. The residue was purified by chromatography (silica gel, 10 g, 200˜300 mesh, methanol:dichloromethane=1:30) to afford 6-(1H-indazol-5-yl)-N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine (48 mg, 38%) as a yellow solid. 1H NMR (300 MHz, DMSO): δ 13.25 (s, 1H), 9.59 (s, 1H), 8.87 (s, 1H), 8.29-8.17 (m, 3H), 7.96 (dd, 1H, J1=8.7 Hz, J2=1.8 Hz), 7.67-7.62 (m, 2H), 7.43 (t, 1H, J=7.8 Hz), 6.73 (d, 1H, J=7.5 Hz), 6.06 (d, 1H, J=8.1 Hz), 4.25-4.21 (m, 1H), 3.63-3.58 (m, 1H), 3.44-3.39 (m, 1H), 2.10-2.05 (m, 3H), 1.70 (s, 1H), 1.12 (d, 3H, J=6.0 Hz). LC-MS: [M+H]+, 411, tR=1.619 min, HPLC: 98.4% at 214 nm, 97.91% at 254 nm, tR=5.848 min.

Workup

  1. concentrationthen concentrated in vacuo
  2. customThe residue was purified by chromatography (silica gel, 10 g, 200˜300 mesh, methanol:dichloromethane=1:30)

Sources & evidence

ORD record
ord-ba9d2f2b7af042fb8d43eb00a052a278
Source dataset
uspto-grants-2015_10
Patent number
US09169259B2

Reaction notes

Loading…